NorthStar Medical Technologies to Present at Upcoming Emerging Medtech Summit 2020 Industry Conference

NorthStar Medical Technologies, LLC, a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced that it will participate in the upcoming Emerging Medtech Summit 2020 conference, being held February 18 ? 20, 2020, in Dana Point, Ca. The Emerging Medtech Summit 2020 brings together top strategists, investors and innovators who are driving the future of healthcare.

Stephen Merrick, President and Chief Executive Officer of NorthStar Medical Technologies, will present and provide an update on NorthStar and its progress in advancing U.S. radioisotope production. Mr. Merrick and Paul Estrem, Senior Vice President and Chief Financial Officer, will conduct meetings with institutional investors in conjunction with the event. Meetings may be arranged by contacting NorthStar Investor Relations. The NorthStar presentation is scheduled for Thursday, February 20, 2020, at 3:55 p.m. Pacific Time, at the Ritz-Carlton Laguna Niguel Hotel.

About NorthStar Medical Technologies, LLC (NorthStar)
NorthStar Medical Radioisotopes is a global innovator in the production and distribution of radioisotopes used for medical imaging and therapeutic purposes. Founded in 2006 and based in Beloit, Wis., NorthStar Medical Technologies is the parent organization of several wholly-owned subsidiaries, including NorthStar Medical Radioisotopes, LLC. NorthStar Medical Radioisotopes is a nuclear medicine technology company committed to providing the United States with reliable and environmentally friendly radioisotope supply solutions to meet the needs of patients and to advance clinical research. The Company's first product is the RadioGenix® System, an innovative and flexible platform technology initially approved by the U.S. Food and Drug Administration in February 2018 for the processing of non-uranium/non-highly enriched uranium based molybdenum-99 (Mo-99), the parent isotope of technetium-99m (Tc-99m), which is currently the most widely used diagnostic radioisotope for medical purposes. NorthStar's proprietary and patented technologies include non-uranium based molybdenum-99 domestic production methods, patented separation chemistry systems, patented sterilization systems and a technology platform that potentially allows expanded product offerings to provide solutions in both the diagnostic and therapeutic markets. For more information, visit: http://www.northstarnm.com.